share_log

藥明合聯：2023年度報告

WUXI XDC: Annual Report 2023

Hong Kong Stock Exchange ·  Apr 29 05:45
Summary by Moomoo AI
WUXI XDC於2023年度報告中宣布，公司財務和運營表現顯示強勁增長，並在戰略上取得重大成就。2023年收入和毛利分別較上年增長114.4%及114.3%，顯示公司業務發展迅速。WUXI XDC成功在香港聯合交易所主板上市，籌集逾40億港元資金，並在新加坡開始建設新製造設施，作為其「全球雙基地製造策略」的一部分。公司在無錫啟用了一個「一體化」製造設施，擴大了產能。作為ADC CRDMO行業的全球領導者，WUXI XDC面對服務需求增加。公司在2023年世界ADC大獎中獲得「最佳合同開發和製造組織(CDMO)」等多項獎項。同時，公司致力於可持續發展和減少環境影響，計劃進一步鞏固市場地位，推動全球生物結合藥物行業的可持續增長。公司對股東、客戶、合作夥伴和員工的貢獻表示感謝，認為這對公司的成功至關重要。
WUXI XDC於2023年度報告中宣布，公司財務和運營表現顯示強勁增長，並在戰略上取得重大成就。2023年收入和毛利分別較上年增長114.4%及114.3%，顯示公司業務發展迅速。WUXI XDC成功在香港聯合交易所主板上市，籌集逾40億港元資金，並在新加坡開始建設新製造設施，作為其「全球雙基地製造策略」的一部分。公司在無錫啟用了一個「一體化」製造設施，擴大了產能。作為ADC CRDMO行業的全球領導者，WUXI XDC面對服務需求增加。公司在2023年世界ADC大獎中獲得「最佳合同開發和製造組織(CDMO)」等多項獎項。同時，公司致力於可持續發展和減少環境影響，計劃進一步鞏固市場地位，推動全球生物結合藥物行業的可持續增長。公司對股東、客戶、合作夥伴和員工的貢獻表示感謝，認為這對公司的成功至關重要。
WUXI XDC ANNOUNCED IN ITS 2023 ANNUAL REPORT THAT THE COMPANY'S FINANCIAL AND OPERATING PERFORMANCE SHOWED STRONG GROWTH AND ACHIEVED SIGNIFICANT STRATEGIC ACHIEVEMENTS. Revenue and gross profit in 2023 grew by 114.4% and 114.3%, respectively, indicating the rapid development of the company's business. WUXI XDC successfully listed on the main board of the Hong Kong Stock Exchange, raised over HK$40 billion and started construction of new manufacturing facilities in Singapore as part of its “Global Dual Base Manufacturing Strategy”. The company has launched an “integrated” manufacturing facility in Wuxi, expanding capacity. As the global leader in the ADC CRDMO industry, WUXI XDC is facing increased service demands. The company won several awards including “Best Contract Development and Manufacturing Organization (CDMO)” at the...Show More
WUXI XDC ANNOUNCED IN ITS 2023 ANNUAL REPORT THAT THE COMPANY'S FINANCIAL AND OPERATING PERFORMANCE SHOWED STRONG GROWTH AND ACHIEVED SIGNIFICANT STRATEGIC ACHIEVEMENTS. Revenue and gross profit in 2023 grew by 114.4% and 114.3%, respectively, indicating the rapid development of the company's business. WUXI XDC successfully listed on the main board of the Hong Kong Stock Exchange, raised over HK$40 billion and started construction of new manufacturing facilities in Singapore as part of its “Global Dual Base Manufacturing Strategy”. The company has launched an “integrated” manufacturing facility in Wuxi, expanding capacity. As the global leader in the ADC CRDMO industry, WUXI XDC is facing increased service demands. The company won several awards including “Best Contract Development and Manufacturing Organization (CDMO)” at the 2023 ADC World Awards. At the same time, the company is committed to sustainability and reducing environmental impacts, and plans to further strengthen its market position and drive the sustainable growth of the global bio-combined drug industry. The company is grateful for the contributions of shareholders, customers, partners and employees, who consider this essential to the success of the company.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more